News

DyNAbind and Almirall enter collaboration agreement

18.05.2020
DyNAbind GmbH and Almirall, a leading skin-health focused pharmaceutical company based in Barcelona (Spain) have entered into a collaboration for compound screening based on DyNAbind’s proprietary DNA-encoded library (DEL) technology. This new partnership aims at discovering novel drug candidates for treating dermatological inflammation.

Michael Thompson, Ph.D, co-founder and CEO of DyNAbind, explains the importance of this deal: “Relevant disease targets of dermatolocial conditions are oftentimes difficult to drug. That’s the reason why diseases like psoriasis to date still represent a huge unmet clinical need and significant burden for patients. We are excited about this new collaboration and the possibility of working together with the Almirall team to help improve the lives of these patients.”

Bhushan Hardas, MD, MBA, CSO, Almirall said: “This exciting collaboration offers an opportunity to discover new drug candidates to develop the right therapies for patients to help them realize their hopes and dreams. We are happy to collaborate with DyNAbind GmbH in this new step.”

Financial terms of the collaboration agreement were not disclosed.

About DyNAbind
DyNAbind GmbH is a privately held company based in Dresden, Germany, offering a next-generation platform of DNA-Encoded Library (DEL) technologies for drug discovery and optimization. DyNAbind’s founders have years of experience in developing and working with DEL technologies, which has driven the development of the novel Dynamic Library platform. By specifically tuning a DNA architecture for transient interactions, fragment molecules in the library dynamically self-assemble and rearrange themselves into ideal binding structures, offering dramatically improved signal-to-noise ratios and reduced false positive hit rates. Follow-up quantitative hit validation can begin without the need for hit resynthesis, allowing meaningful results to arrive in days instead of months.

Our entire team at DyNAbind is dedicated to working with our partners to develop and implement the most effective discovery and optimization programs for any drug target. Whether your program is coming from the pharma, biotech or academic sector, we’re motivated to help you find the best path to higher-quality, more relevant medicinal chemistry starting points.

About Almirall:
For further information please visit the Almirall website at:
https://www.almirall.com/

Press contact:
DyNAbind GmbH
Nadine Schmieder-Galfe
Director Marketing
+49 (0)351 7999 2923
info@dynabind.com
http://www.dynabind.com

Quelle: Pressemitteilung DyNabind GmbH vom 18.05.2020